<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a varied group of diseases leading to significant morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Therapy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option </plain></SENT>
<SENT sid="2" pm="."><plain>Agents, such as the <z:chebi fb="0" ids="17562">cytidine</z:chebi> analog <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, exert an effect on DNA methyltransferase leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, <z:chebi fb="0" ids="2038">azacitidine</z:chebi> has been shown to prolong survival and improve quality of life in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, while maintaining a favorable adverse effect profile </plain></SENT>
<SENT sid="4" pm="."><plain>This review highlights the scientific rationale for the use of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in addition to its application in current clinical practice for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>